Peninsula Medical School, University of Plymouth
Plymouth, United Kingdom
Prof. Dr. Clemens Oliver Hanemann, MD, PhD, FRCP
Associate Head of School (Research) Peninsula Medical School since 12/2019
Director South West Brain Tumour Research Center of Excellenece since 9/2014
Chair in clinical Neurobiology Peninsula Medical School since 11/2005
Consultant in Neurology Plymouth Hospital Trust since 1/2006
I have supervised more than 21 MD and PhD students, the vast majority of my students are still in academia or pharmaceutical industry, some at group leader level. I have published more tha 16 papers; my h-index is 53. I am an active member of ICOM, the NCRI and have additional roles in Brain Research Trust, EANO and WFNOS. I have been working on brain tumors esp. Schwannoma and meningioma since 2003. In the last couple of years, my research focus is on meningioma.
• My research in brain tumours includes more basic work on understanding the role of common tumour suppressor merlin (NF2 gene product). NF2 gene is one of the most common mutated genes in brain tumours. This more basic work is reflected in over 40 publications including below
Li W, You L, eta l (2010). Cell, 140:477-90, Sher, CO Hanemann, PA Karplus, and AP Bretscher (2012). Dev Cell 22(4):703-5.
• As a clinical academic I try to translate our result into clinical trials as exemplified by
Ammoun S, Flaiz C, Ristic N, Hanemann CO (2008), Cancer Research, 68:5236-5245 and Ammoun Sylwia, Hilton David, Gareth Evans, Streeter Adam, Hayward Chris, Hanemann C Oliver, 2019 Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in NF2, JNNP, doi: 10.1136/jnnp-2018-319713
• Recently we have been using omics to discover new drug targets and biomarkers in meningioma Collard G, T et al. (2018), Dunn et al (2019,2020), Negroni et al (2020)